Cyclotron production of [68Ga]GaCl3 using solid target and its clinical adaptation through automated purification and GMP-grade production of [68Ga]Ga-DOTATATE

In the world of modern medicine, doctors often need to see inside the body not just to find a lump, but to understand how a specific disease is behaving at a cellular level. For patients with neuroendocrine tumors, a type of growth that can be difficult to locate, a special kind of imaging has become essential. This technique uses a tiny amount of a radioactive metal called gallium-68, attached to a molecule that acts like a homing beacon. This beacon seeks out and sticks to the tumor cells, lighting them up on a scanner so doctors can see exactly where they are. This process is part of a larger approach called theranostics, where the same targeting method used to find the disease is also used to treat it. However, getting enough of this radioactive gallium to scan patients has become a major hurdle. The traditional way to make it relies on a device that slowly releases the metal over time, but this method often cannot produce enough material for large hospitals, and the logistics of shipping it are difficult and expensive.

To solve this bottleneck, researchers have developed a new way to make gallium-68 using a particle accelerator, known as a cyclotron, which is already found in many medical centers. Instead of waiting for a slow release from a generator, this new method smashes protons into a solid block of zinc to create the radioactive gallium directly. The team behind this work built a complete system to handle the entire process, from preparing the zinc target to cleaning up the final product. They designed a workflow that could be moved to different hospitals, allowing them to produce a large amount of the radioactive material on demand. Once the gallium was created, they used an automated machine to attach it to the targeting molecule, creating the final drug used for scanning patients.

The results of this new approach were substantial. By firing a beam of protons at a solid zinc target for two hours, the team was able to produce between 90 and 110 gigabecquerels of the radioactive gallium chloride. This is a significant amount of activity, enough to supply many patients at once. The process was highly efficient, recovering more than half of the potential radioactive material, and the final product was extremely pure, containing almost no unwanted impurities. The researchers then took this freshly made material and, using a specialized automated module, turned it into the final scanning drug, gallium-68 DOTATATE. They were able to do this under strict safety and quality standards required for human use, completing the synthesis in about five hours with high success rates and purity levels that met all medical requirements.

This work demonstrates that hospitals do not need to rely entirely on external suppliers or the limited output of traditional generators to get the scanning drugs they need. By using a solid target and a cyclotron, medical centers can create a self-sufficient supply of gallium-68. The team showed that this method is scalable and reliable, offering a practical path for regional production. Rather than inventing a completely new type of target or waiting for outside help, this study proves that existing cyclotron infrastructure can be adapted to produce not only gallium-68 but potentially other emerging radioactive metals as well. This shift allows medical facilities to maximize their current equipment and ensure that patients receive the timely, high-quality imaging necessary for effective care.